Drug intelligence / Profile preview

Ebola Peptide Vaccine

Development stage: Unknown
Lead developer: Merck
Modality: Peptides, Vaccines & Immunotherapeutics

Overview

Ebola Peptide Vaccine is an epitope-based peptide vaccine candidate developed by Asia Biotech for the prevention of Ebola virus disease. It is designed using the company's proprietary Epitope Platform to stimulate a targeted immune response against specific viral peptide sequences. The vaccine was reported to have successfully completed Phase 2 clinical trials by the end of 2016, though further development updates have been limited.

Other names: Epitope-based Ebola vaccine

Targets

MHC I (MHC class I})

Beyond the preview

Go deeper on Ebola Peptide Vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ebola Peptide Vaccine.

Explore the full profile